Cargando…

Inflammation as a Therapeutic Target in Cancer Cachexia

SIMPLE SUMMARY: Weight loss, called cachexia, often occurs in cancer patients, and is associated with poor quality of life and shorter survival. Cancer cachexia is associated with increased circulating inflammatory factors, but efforts to reduce levels of inflammation using a single agent have not b...

Descripción completa

Detalles Bibliográficos
Autores principales: Clamon, Gerald, Byrne, Margaret M., Talbert, Erin E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9657920/
https://www.ncbi.nlm.nih.gov/pubmed/36358681
http://dx.doi.org/10.3390/cancers14215262
_version_ 1784829817081823232
author Clamon, Gerald
Byrne, Margaret M.
Talbert, Erin E.
author_facet Clamon, Gerald
Byrne, Margaret M.
Talbert, Erin E.
author_sort Clamon, Gerald
collection PubMed
description SIMPLE SUMMARY: Weight loss, called cachexia, often occurs in cancer patients, and is associated with poor quality of life and shorter survival. Cancer cachexia is associated with increased circulating inflammatory factors, but efforts to reduce levels of inflammation using a single agent have not been successful. Cachexia likely results from many causes, including inflammatory cytokines, anorexia, catabolism, depression, and pain, and targeting the multiple causes will likely be necessary to achieve improvement in weight and appetite. In this review, we explore some potential therapies to address the need for anti-cachexia therapy with an emphasis on existing therapies that may be able to be re-purposed, therapies targeting inflammation, and the likely need for combination therapy directed at the complex causes of cancer cachexia. ABSTRACT: Cachexia is a common complication of cancer and is associated with poor quality of life and a decrease in survival. Many patients with cancer cachexia suffer from inflammation associated with elevated cytokines, such as interleukin-1beta (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor (TNF). Single-agent trials to treat cancer cachexia have not led to substantial benefit as the type of cytokine which is elevated has rarely been specified and targeted. Cachexia may also be multifactorial, involving inflammation, anorexia, catabolism, depression, and pain, and targeting the multiple causes will likely be necessary to achieve improvement in weight and appetite. A PUBMED search revealed over 3000 articles on cancer cachexia in the past ten years. We attempted to review any studies related to inflammation and cancer cachexia identified by Google Scholar and PUBMED and further search for articles listed in their references. The National Comprehensive Cancer Network (NCCN) guidelines do not provide any suggestion for managing cancer cachexia except a dietary consult. A more targeted approach to developing therapies for cancer cachexia might lead to more personalized and effective therapy.
format Online
Article
Text
id pubmed-9657920
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96579202022-11-15 Inflammation as a Therapeutic Target in Cancer Cachexia Clamon, Gerald Byrne, Margaret M. Talbert, Erin E. Cancers (Basel) Review SIMPLE SUMMARY: Weight loss, called cachexia, often occurs in cancer patients, and is associated with poor quality of life and shorter survival. Cancer cachexia is associated with increased circulating inflammatory factors, but efforts to reduce levels of inflammation using a single agent have not been successful. Cachexia likely results from many causes, including inflammatory cytokines, anorexia, catabolism, depression, and pain, and targeting the multiple causes will likely be necessary to achieve improvement in weight and appetite. In this review, we explore some potential therapies to address the need for anti-cachexia therapy with an emphasis on existing therapies that may be able to be re-purposed, therapies targeting inflammation, and the likely need for combination therapy directed at the complex causes of cancer cachexia. ABSTRACT: Cachexia is a common complication of cancer and is associated with poor quality of life and a decrease in survival. Many patients with cancer cachexia suffer from inflammation associated with elevated cytokines, such as interleukin-1beta (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor (TNF). Single-agent trials to treat cancer cachexia have not led to substantial benefit as the type of cytokine which is elevated has rarely been specified and targeted. Cachexia may also be multifactorial, involving inflammation, anorexia, catabolism, depression, and pain, and targeting the multiple causes will likely be necessary to achieve improvement in weight and appetite. A PUBMED search revealed over 3000 articles on cancer cachexia in the past ten years. We attempted to review any studies related to inflammation and cancer cachexia identified by Google Scholar and PUBMED and further search for articles listed in their references. The National Comprehensive Cancer Network (NCCN) guidelines do not provide any suggestion for managing cancer cachexia except a dietary consult. A more targeted approach to developing therapies for cancer cachexia might lead to more personalized and effective therapy. MDPI 2022-10-26 /pmc/articles/PMC9657920/ /pubmed/36358681 http://dx.doi.org/10.3390/cancers14215262 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Clamon, Gerald
Byrne, Margaret M.
Talbert, Erin E.
Inflammation as a Therapeutic Target in Cancer Cachexia
title Inflammation as a Therapeutic Target in Cancer Cachexia
title_full Inflammation as a Therapeutic Target in Cancer Cachexia
title_fullStr Inflammation as a Therapeutic Target in Cancer Cachexia
title_full_unstemmed Inflammation as a Therapeutic Target in Cancer Cachexia
title_short Inflammation as a Therapeutic Target in Cancer Cachexia
title_sort inflammation as a therapeutic target in cancer cachexia
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9657920/
https://www.ncbi.nlm.nih.gov/pubmed/36358681
http://dx.doi.org/10.3390/cancers14215262
work_keys_str_mv AT clamongerald inflammationasatherapeutictargetincancercachexia
AT byrnemargaretm inflammationasatherapeutictargetincancercachexia
AT talberterine inflammationasatherapeutictargetincancercachexia